Warren P. Mason

机构：University of Toronto, Princess Margaret Cancer Centre · ORCID：0000-0001-9107-2242

发表论文 392 篇 · 总被引 59801 次 · h-index 65

代表论文

• Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trial (2025 · The Lancet Oncology · 被引 35)
• A population-based analysis of the molecular landscape of glioma in adolescents and young adults reveals insights into gliomagenesis (2025 · Nature Cancer · 被引 18)
• Canadian Expert Consensus Recommendations for the Diagnosis and Management of Glioblastoma: Results of a Delphi Study (2025 · Current Oncology · 被引 7)
• Final clinical and molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q codeletion: NCT00626990. (2025 · Journal of Clinical Oncology · 被引 5)
• Temozolomide Versus Radiotherapy as First-Line Therapy for Low-Grade Glioma: Mature Results of a Randomized Phase III Trial (EORTC 22033-26033/NCIC-CTG/TROG/MRC-CTU) (2026 · Journal of Clinical Oncology · 被引 4)
• Author Correction: Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial (2025 · Nature Medicine · 被引 3)